Roivant Sciences

Roivant Sciences Reports Financial Results for the First Quarter Ended June 30, 2022 and Provides Business Update

Retrieved on: 
Monday, August 15, 2022 - 12:00pm

First Quarter Ended June 30, 2022 Financial Summary

Key Points: 
  • First Quarter Ended June 30, 2022 Financial Summary
    As of June 30, 2022, we had cash, cash equivalents and restricted cash of approximately $2.0 billion.
  • Net loss was $353.8 million for the three months ended June 30, 2022 compared to $101.1 million for the three months ended June 30, 2021.
  • On a per common share basis, net loss was $0.48 for the three months ended June 30, 2022 and $0.13 for the three months ended June 30, 2021.
  • Non-GAAP net loss was $210.7 million for the three months ended June 30, 2022 compared to $133.4 million for the three months ended June 30, 2021.

Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis

Retrieved on: 
Saturday, August 6, 2022 - 1:50am

MYFEMBREE offers an effective, once-daily treatment option for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.

Key Points: 
  • MYFEMBREE offers an effective, once-daily treatment option for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.
  • MYFEMBREE is available immediately to patients with moderate to severe pain associated with endometriosis with a prescription from their healthcare provider.
  • Myovant and Pfizer also are committed to supporting women in the U.S. who are prescribed MYFEMBREE throughout their treatment journeys.
  • Food and Drug Administration for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.

Arbutus Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 4, 2022 - 12:30pm

WARMINSTER, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today reports its second quarter 2022 financial results and provides corporate updates.

Key Points: 
  • WARMINSTER, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today reports its second quarter 2022 financial results and provides corporate updates.
  • Finally, our financial position is strong with a projected cash runway into the second quarter of 2024.
  • The Company is on-track to report initial data in the second half of 2022.
  • The Company will provide an update with respect to the status and timing of this clinical trial in the second half of 2022.

Roivant Sciences to Report Financial Results for the Quarter Ended June 30, 2022 on Monday, August 15, 2022

Retrieved on: 
Wednesday, August 3, 2022 - 12:00pm

A webcast of the call will also be available under Events & Presentations in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events .

Key Points: 
  • A webcast of the call will also be available under Events & Presentations in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events .
  • In addition, Roivant will host a virtual investor day on Wednesday, September 28, at 11:00 a.m. EDT in order to provide updates across Roivant and the Vants.
  • Roivant's mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity.
  • The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

Differentiated Therapeutics Raises $5 Million Seed Round

Retrieved on: 
Monday, August 1, 2022 - 1:00pm

Differentiated Therapeutics (dx/tx), a biotech company focused on computationally predicting and optimizing targeted protein degraders (TPDs), today announced the completion of a $5 million Seed financing.

Key Points: 
  • Differentiated Therapeutics (dx/tx), a biotech company focused on computationally predicting and optimizing targeted protein degraders (TPDs), today announced the completion of a $5 million Seed financing.
  • Differentiated Therapeutics was founded by CEO Bryce Allen, PhD, COO Diala Ezzeddine, PhD, and Professor Isaac Kohane, MD PhD, of Harvard Medical School (HMS).
  • Bryce Allen has a demonstrated track record in developing innovative computational approaches to designing small molecule therapeutics, most recently as a founding member of Silicon Therapeutics, acquired by Roivant Sciences in 2021 for $450 million.
  • Differentiated Therapeutics mission is to design and develop disease-modifying TPD therapies for patients with unmet medical need.

Innovaderm Shines as Key Partner in Clinical Development and Study Management of Newly FDA-Approved Psoriasis Drug, Tapinarof

Retrieved on: 
Thursday, July 21, 2022 - 4:00pm

Innovaderm is well-positioned to help companies such as Dermavant drive innovation forward by accompanying them in all stages of their clinical research from protocol writing to data analysis.

Key Points: 
  • Innovaderm is well-positioned to help companies such as Dermavant drive innovation forward by accompanying them in all stages of their clinical research from protocol writing to data analysis.
  • Currently, clinical trials are underway to study this medication among patients with atopic dermatitis.
  • Indication: VTAMA (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist approved in the US for the topical treatment of plaque psoriasis in adults.
  • Founded in 2000, it partners with biotechnology and pharmaceutical companies for the collaborative management of early to late phase clinical trials.

Myovant Sciences to Host First Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m. Eastern Time on July 27, 2022

Retrieved on: 
Wednesday, July 13, 2022 - 11:45am

BASEL, Switzerland, July 13, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for its first fiscal quarter, ended June 30, 2022.

Key Points: 
  • BASEL, Switzerland, July 13, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for its first fiscal quarter, ended June 30, 2022.
  • The webcast and conference call will be held at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on July 27, 2022.
  • The live webcast can also be accessed by visiting the companys investor relations page of Myovants website at: https://investors.myovant.com/ .
  • Myovant Sciencesaspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy.

Jessica Meng Joins Delfi Diagnostics as Chief Commercial Officer

Retrieved on: 
Tuesday, July 12, 2022 - 1:00pm

BALTIMORE, July 12, 2022 /PRNewswire/ -- Delfi Diagnostics, Inc., a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, has hired Jessica Meng as the company's first Chief Commercial Officer.

Key Points: 
  • BALTIMORE, July 12, 2022 /PRNewswire/ -- Delfi Diagnostics, Inc., a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, has hired Jessica Meng as the company's first Chief Commercial Officer.
  • "Jessica is a strategic leader who has scaled commercial organizations in therapeutics and diagnostics and knows what it takes to commercialize successful oncology products," said Delfi Founder and CEO Victor Velculescu, MD, PhD.
  • "We are excited to have her leadership as we prepare to introduce the first products on the Delfi platform."
  • Jessica is a proven commercial leader with a 20+ year track record in healthcare and extensive product launch leadership.

VUMC and Roivant Social Ventures Announce Collaboration to Develop Therapies for Underserved Populations

Retrieved on: 
Wednesday, July 6, 2022 - 2:00pm

NEW YORK, July 06, 2022 (GLOBE NEWSWIRE) -- Vanderbilt University Medical Center ( VUMC ) and Roivant Social Ventures ( RSV ) announced an intention to collaborate in developing therapies for traditionally underserved populations and diseases.

Key Points: 
  • NEW YORK, July 06, 2022 (GLOBE NEWSWIRE) -- Vanderbilt University Medical Center ( VUMC ) and Roivant Social Ventures ( RSV ) announced an intention to collaborate in developing therapies for traditionally underserved populations and diseases.
  • RSV is a not-for-profit social impact organization founded by executives from Roivant Sciences that is focused on improving health equity.
  • Specifically, the non-profit will work with the Vanderbilt Institute for Clinical and Translational Research ( VICTR ) and its Drug Repurposing program .
  • We are thrilled to partner with VUMC and VICTR and, together, apply this experience and knowledge in a targeted way to help underserved patient populations.

Eloxx Pharmaceuticals Announces Changes to Board of Directors

Retrieved on: 
Tuesday, July 5, 2022 - 1:00pm

WATERTOWN, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the appointment of Lindsay Androski, JD, MBA to its board of directors and as a member of the Board’s Audit Committee and Compensation Committee. Current board members Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr. Jasbir Seehra have stepped down from the board. Following these changes, Eloxx’s board is now comprised of five directors.

Key Points: 
  • Current board members Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr. Jasbir Seehra have stepped down from the board.
  • Following these changes, Eloxxs board is now comprised of five directors.
  • I am passionate about companies like Eloxx that are focused on addressing unmet needs for underserved patient populations.
  • I am excited to join the board of Eloxx and to contribute to the companys work in developing therapies for rare diseases, said Ms. Androski.